Abstract
Non-specific distribution of chemotherapeutic agents in the body where they affect both cancer as well as normal cells resulting in serious side effects is the major reason for the high mortality rate of cancer. Thus, there is a need for developing targeted delivery strategies specially employing nanoplatform-based cancer therapies that provide specific targeting to tumor cells. In this regard, biopolymeric nanoplatforms such as liposomes, protein- and polysaccharide- based nanoparticles have gained more attention due to their biocompatibility, biodegradability and less toxicity. In terms of targeting, monoclonal antibodies (mAbs), folic acid (FA) and transferrin (Tf) can be considered as the moieties to be attached to the nanoplatforms to deliver their payload to its site of action. This review article focuses on the recent progress in the field of targeted drug and gene delivery systems with emphasizes on liposomes, protein (specially human and bovine serum albumin)-based nanoparticles and polysaccharide (specially chitosan and dextran)-based nanoparticles as the biopolymeric nanoplatforms, which are decorated with mAbs, FA and Tf as the targeting ligands.
Keywords: Biopolymeric nanoplatforms, cancer targeting, monoclonal antibody, folic acid, transferrin, polysaccharide.
Current Pharmaceutical Design
Title:Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Volume: 23 Issue: 35
Author(s): Hasan Kouchakzadeh*, Tooba Soudi, Niloofar Heshmati Aghda and Seyed Abbas Shojaosadati*
Affiliation:
- Protein Research Center, Shahid Beheshti University, G.C., Velenjak, Tehran,Iran
- Biotechnology Group, Chemical Engineering Faculty, Tarbiat Modares University, Tehran,Iran
Keywords: Biopolymeric nanoplatforms, cancer targeting, monoclonal antibody, folic acid, transferrin, polysaccharide.
Abstract: Non-specific distribution of chemotherapeutic agents in the body where they affect both cancer as well as normal cells resulting in serious side effects is the major reason for the high mortality rate of cancer. Thus, there is a need for developing targeted delivery strategies specially employing nanoplatform-based cancer therapies that provide specific targeting to tumor cells. In this regard, biopolymeric nanoplatforms such as liposomes, protein- and polysaccharide- based nanoparticles have gained more attention due to their biocompatibility, biodegradability and less toxicity. In terms of targeting, monoclonal antibodies (mAbs), folic acid (FA) and transferrin (Tf) can be considered as the moieties to be attached to the nanoplatforms to deliver their payload to its site of action. This review article focuses on the recent progress in the field of targeted drug and gene delivery systems with emphasizes on liposomes, protein (specially human and bovine serum albumin)-based nanoparticles and polysaccharide (specially chitosan and dextran)-based nanoparticles as the biopolymeric nanoplatforms, which are decorated with mAbs, FA and Tf as the targeting ligands.
Export Options
About this article
Cite this article as:
Kouchakzadeh Hasan*, Soudi Tooba , Aghda Heshmati Niloofar and Shojaosadati Abbas Seyed *, Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy, Current Pharmaceutical Design 2017; 23 (35) . https://dx.doi.org/10.2174/1381612823666170526101408
DOI https://dx.doi.org/10.2174/1381612823666170526101408 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Resistance to Type II Topoisomerase Inhibitors
Current Medicinal Chemistry Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Bioconjugation of Polymers: A Novel Platform for Targeted Drug Delivery
Current Pharmaceutical Design Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond
Current Cancer Drug Targets Oncogenic Properties of HIV-Tat in Colorectal Cancer Cells
Current HIV Research p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Ex Vivo Gene Therapy and Vision
Current Gene Therapy Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review
Current Drug Therapy Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
Current Pharmaceutical Design Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Fluoroquinolone and Ovariectomy in the Bitch: Physiology of the Immune System as to CD56 and CD16 Expression
Endocrine, Metabolic & Immune Disorders - Drug Targets The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) Molecular Targeted Therapy of Gastrointestinal Stromal Tumors
Current Cancer Drug Targets Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy